Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Zhu Website

Zhongyu Zhu, Ph.D.

Laboratory of Experimental Immunology
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 567, Room 180
Frederick, MD 21702-1201
Phone:  
301-846-5809
Fax:  
301-846-5598
E-Mail:  
zhuzhongyu@mail.nih.gov

Biography

Dr. Zhongyu Zhu obtained his Ph.D. from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He came to the NCI for his postdoctoral research training and then became a staff scientist in Dr. Dimiter Dimitrov's group in the CCR Nanobiology Program. Currently, Dr. Zhu is with the Laboratory of Experimental Immunology, Cancer and Inflammation Program. Dr. Zhu's research interests focus on therapeutic antibody development through antibody engineering.

Research

Antibodies are a key component of the immune system, playing a central role in antigen/pathogen recognition and stimulation of immune response, and also functioning as a huge collection of naturally produced medicine targeting various diseases.

Our research interests focus on antibody-based therapeutics development through phage and yeast display antibody library technology. Working together with our collaborators, we are particularly interested in the following three categories:

1) Naked Antibody: Full-size antibody can serve as a modulator of disease-causing protein-protein interactions and mediator of immune responses toward disease targets for drug development.

2) Antibody-Drug Conjugates (ADCs): ADCs provide biomarker-targeted delivery of toxic drug for cancer therapy.

3) Chimeric Antigen Receptors (CARs): Engineered antibody fragment can be expressed as CARs on T cells for cancer biomarker-targeted T cell-based immunotherapy.

This page was last updated on 5/29/2014.